NEO212 inhibits migration and invasion of glioma stem cells

February 2018 Molecular Cancer Therapeutics 2018, Feb. 13 [E-pub ahead of print] CLICK HERE This preclinical study reveals a second anticancer feature of NEO212: in addition to its well-established tumor killing effect, it can also inhibit the migration of brain tumor stem cells. The migration of tumor stem cells allows…

Continue reading

A perillyl alcohol-conjugated analog of 3-bromopyruvate without cellular uptake dependency on monocarboxylate transporter 1 and with activity in 3-BP-resistant tumor cells

August 2017 Cancer Letters 2017, 400:161. CLICK HERE ➔ to full-length paper, which might require a subscription This is the first published report on our proprietary compound NEO218, which consists of perillyl alcohol conjugated to 3-bromopyruvate (3-BP). Although 3-BP has anticancer activity of its own, some tumor cells are able…

Continue reading

NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas.

August 2014 Molecular Cancer Therapeutics 2014, 13:2004. CLICK HERE This report on compound NEO212 demonstrates its cancer therapeutic potency in cell culture and mouse models of glioblastoma (GBM), the most deadly form of primary brain cancer. It is observed in clinical practice that nearly all these patients eventually stop responding…

Continue reading

A Novel Temozolomide Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells in vitro and Intracranial Triple-Negative Tumor Growth in vivo

May 2014 Molecular Cancer Therapeutics 2014, 13:1181. CLICK HERE This report on compound NEO212 demonstrates its cancer therapeutic potency in cell culture and mouse models of triple-negative breast cancer, a particularly aggressive subtype of breast cancer that tends to spread and reoccur despite the best current treatments. This study finds…

Continue reading

Perillyl alcohol for the treatment of temozolomide-resistant gliomas

November 2012 Molecular Cancer Therapeutics 2012, 11:2462. CLICK HERE The development of treatment resistance represents an enormous problem for cancer therapy in general. In the case of malignant gliomas in particular, standard treatment approaches inevitably fail, leaving the patient with no effective further treatment options. This preclinical study demonstrated that…

Continue reading